FIELD: bioengineering.
SUBSTANCE: polypeptide with length below 100 aminoacids is suggested. The polypeptide contains sequence selected out of SEQ ID NO: 2, 3, 4, 7 or 8, or its immunogen fragment containing 8 aminoacids. The mixture of the polypeptides is suggested, it contains the first and the second polypeptides that differ from each other. Besides the pharmaceutical composition is suggested, it contains the above said polypeptide or mixture of the polypeptides. The method of medical treatment or preventive treatment of cancer is suggested with use of the said polypeptide, mixture of the polypeptides or the pharmaceutical composition.
EFFECT: group of inventions has increased immunogenicity during vaccination in comparison with the full-size protein hTERT, and ensures stimulation of T-cell immune response and increases duration of survival.
20 cl, 19 dwg, 10 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED PROTEIN OF TELOMERASE REVERSE TRANSCRIPTASE, NUCLEOTIDES CODING THEM, AND USING THEM | 2007 |
|
RU2473691C2 |
| VACCINE AGAINST HERPES SIMPLEX VIRUS TYPE 2: COMPOSITIONS AND METHODS FOR TRIGGERING IMMUNE RESPONSE | 2010 |
|
RU2585961C9 |
| COMPOSITIONS AND METHODS OF TREATING FUNGAL AND BACTERIAL PATHOGENS | 2014 |
|
RU2717306C2 |
| IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2648791C2 |
| FUSED POLYPEPTIDES AND VACCINES | 2014 |
|
RU2699006C2 |
| MULTIVALENT VACCINE AGAINST BREAST CANCER | 2013 |
|
RU2645085C2 |
| RECOMBINANT VACCINE OF FELINE LEUKEMIA VIRUS CONTAINING OPTIMISED GENE OF FELINE LEUKEMIA VIRAL ENVELOPE | 2012 |
|
RU2591817C2 |
| VACCINE COMPOSITION FOR TREATMENT OF CANCER | 2018 |
|
RU2782261C2 |
| DNA COMPOSITION FOR INDUCING IMMUNE RESPONSE ON TUMOUR-ASSOCIATED MACROPHAGUES | 2007 |
|
RU2459631C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC REGIMENS BASED ON VACCINES | 2013 |
|
RU2737765C2 |
